Lessons Learned
mCRPC, castrate-resistant prostate cancer
CASTRATE-RESISTANT PROSTATE CANCER
The addition of avelumab did not demonstrate clinical activity in a cohort of Black men with metastatic castrate-resistant prostate cancer (mCRPC) that had progressed on abiraterone acetate or enzalutamide.Black men with mCRPC had a short interval between PSA and radiographic/clinical progression on this trial.